Oral PDE4B Inhibitor Gets Breakthrough Tx Status for Idiopathic Pulmonary Fibrosis
The FDA has granted Breakthrough Therapy designation to BI 1015550 for the treatment of idiopathic pulmonary fibrosis.
Source: empr.com
Page 2 - Thomas Seck News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomas Seck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomas Seck Today - Breaking & Trending Today
Boehringer wins FDA Breakthrough Therapy Designation for oral therapy
The US FDA has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550 to treat IPF.
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
/PRNewswire/ -- Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA)...
Source: prnewswire.com
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
/PRNewswire/ -- Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA)...
Source: prnewswire.com
Biosimilar Cyltezo® shows similar clinical outcomes to Humira® in treatment of moderate-to-severe chronic plaque psoriaris | Goodwin
To embed, copy and paste the code into your website or blog: Boehringer Ingelheim announced earlier this week that results from a phase III study showed that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in the treatment of people with moderate-to-severe chronic plaque psoriasis. The results support Boehringer Ingelheim’s supplemental biologics application to designate Cyltezo® as an interchangeable biosimilar to Humira®. The action date is scheduled for the 4th quarter of 2021. Thomas Seck, Senior Vice President ...
Source: jdsupra.com